The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Subscribe To Our Newsletter & Stay Updated